Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors

Background: Breast cancer (BC) represents the most common cancer in women worldwide. Due to its heterogeneous nature, breast cancer management might benefit from differential treatments toward personalized medicine. Additionally, drug resistance is a common phenomenon. We systematically investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Baldassari, Federica, Zerbinati, Carlotta, Galasso, Marco, Corrà, Fabio, Minotti, Linda, Agnoletto, Chiara, Previati, Maurizio, Croce, Carlo M., Volinia, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968201/
https://www.ncbi.nlm.nih.gov/pubmed/29868122
http://dx.doi.org/10.3389/fgene.2018.00174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968201/
https://www.ncbi.nlm.nih.gov/pubmed/29868122
http://dx.doi.org/10.3389/fgene.2018.00174

Ejemplares similares